In vivo antitumor evaluation of antibiotics. Selected results from the Drug Evaluation Program of the National Cancer Institute, U.S.A.
A summary is given of the in vivo screening results for selected antitumor antibiotics in various stages of the National Cancer Institute drug development program. In addition a brief description of general screening practices of the program is given. After long-term usage of leukemia L1210 as a primary screen, a new screening panel is being initiated with P388 leukemia as a prescreening system. Illustrative data on anguidine, actinomycin D, macromomycin, aclacinomycin, and other fermentation products are shown.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002478:Cells, Cultured; D004353:Drug Evaluation, Preclinical; D051379:Mice; D009316:National Institutes of Health (U.S.); D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D051381:Rats; D014184:Transplantation, Homologous; D014481:United States
D000903:Antibiotics, Antineoplastic